Skip to main content
OpenTrials
Completed

NCT Number: NCT00477841

Self-Expandable Esophageal Radiation Stent:a Randomized Controlled Trial in Patients With Advanced Esophageal Cancer

To determine the response to treatment with a novel esophageal stent loaded with 125I seeds for intraluminal brachytherapy versus a conventional covered stent in patients with advanced esophageal cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Zhongda Hospital, Southeast University

Nanjing, Jiangsu, 210009, China

About this study

Esophageal cancer is common in some areas , ranking as the fourth leading cause of death from cancer in China and sixth worldwide. Although the prognosis of surgical resection for esophageal cancer has been improved, more than 50% of such patients are inoperable and have to undergo palliative treatments because of late stage cancer or metastasis. Dysphagia is the predominate symptom of patients with inoperable esophageal cancer. To relieve the dysphagia and improve the quality of life of such patients, brachytherapy has previously been utilized. Recently, stent placement has been widely accepted to be an option for palliation of the symptoms due to the esophageal strictures. However, recurrence of the neoplastic stricture remains a challenge after stent placement. To combine the advantages of the immediate relief of the esophageal dysphagia with the stent placement and radiation therapy with brachytherapy, a novel esophageal stent loaded with 125I seeds has been developed in the authors' institute. The technical feasibility and safety with this new stent has been demonstrated to be adequate in a healthy rabbit model. The current study is designed to demonstrate the preliminary results with this irradiation stent in patients with inoperable esophageal cancer compared to those using a conventional covered stent.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically confirmed primary cancer of esophagus,
  • Must be dysphagia caused by esophageal cancer,
  • Surgically inoperable, but may be metastatic,
  • Without esophageal fistulas,
  • Must be an inpatient at Zhongda Hospital,
  • Life expectancy is over 6 months,

Exclusion criteria

  • Esophageal fistulas,
  • Tracheal compression with symptoms,
  • WBC <2000/mm3 and Platelet count <50,000/mm3,
  • Concurrent therapies:surgery, chemotherapy,radiotherapy, Traditional Chinese Medicine

Treatment and study plan

Esophageal stent placement

Procedure

dysphagia scores

Procedure

complications of therapy

Procedure

survival time of therapy

Procedure

Primary outcomes

  1. Relief of dysphagia measured by dysphagia scores, survival time from the interventional procedure to the last follow-up.

    Time frame: Follow-up in intervals of 1, 3, 6 and 12 months after stent placement

Secondary outcomes

  1. Successful rate of stent placement, Stent-related complications and morbidity, Overall rate of mortality

    Time frame: Follow-up in intervals of 1, 3, 6, and 12 months after stent placement

Sponsors and collaborators

Lead sponsor

Southeast University, China

Other

Registry information

Important dates

Study start
2004
Study completion
2006
First posted
May 24, 2007
Registry last updated
Apr 18, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.